In treatment decision-making the following points should also be considered. Evolution of a non-toxic to a toxic nodule has been variously estimated at rates of 0-6% per year, with a total of 130 patients out of 965 (13.5%) evolving to thyrotoxicosis over a mean followup of 2-9 years (11). The differences in these studies may be related to the different iodine-intake areas evaluated (12) , as well as to the duration of follow-up and the criteria used to define euthyroidism and thyrotoxicosis. A reasonable estimate based on the largest study is 4.1% per year (11) . Iodine (14) . The risk of associated thyroid malignancy is also considered low by most investigators (1, 2, 15, 16 (36) .
On the whole, it appears that hypothyroidism is a, not uncommon long-term consequence of radioiodine treatment that has not been eliminated by any type of dose planning (28 
